An Open Label, Single Dose, Randomized, Two-Way Cross-Over Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination Rifampicin + Isoniazid (Myrin 2, Pfizer Inc) Tablet With The Reference Drug (Rimactane, Novartis Sandoz) Capsule In Healthy Filipino Male Subjects.

Trial Profile

An Open Label, Single Dose, Randomized, Two-Way Cross-Over Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination Rifampicin + Isoniazid (Myrin 2, Pfizer Inc) Tablet With The Reference Drug (Rimactane, Novartis Sandoz) Capsule In Healthy Filipino Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2015

At a glance

  • Drugs Isoniazid/rifampicin (Primary) ; Rifampicin
  • Indications Tuberculosis
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 02 Jun 2011 Planned end date changed from 1 May 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top